N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 22.3 NOK 1.83% Market Closed
Market Cap: 393.8m NOK

EV/EBIT
Enterprise Value to EBIT

11.9
Current
15.1
Median
16.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
11.9
=
Enterprise Value
428m NOK
/
EBIT
36.1m NOK
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 706.1
11.9
33%
0.4
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.5
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.8
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
11
2-Years Forward
EV/EBIT
7.4
3-Years Forward
EV/EBIT
5.7